A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
A Phase 1, Investigator- and Participant-Blinded, Placebo Controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
Sponsor: Eli Lilly and Company
Listed as NCT06916091, this PHASE1 trial focuses on Obesity and Overweight and remains completed. Sponsored by Eli Lilly and Company, it has been updated 4 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Aug 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jul 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Apr 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .